TKNO vs. VNRX, ABIO, ICCC, CODX, AWH, AXDX, OCX, DMTK, ACHV, and MRNS
Should you be buying Alpha Teknova stock or one of its competitors? The main competitors of Alpha Teknova include VolitionRx (VNRX), ARCA biopharma (ABIO), ImmuCell (ICCC), Co-Diagnostics (CODX), Aspira Women's Health (AWH), Accelerate Diagnostics (AXDX), OncoCyte (OCX), DermTech (DMTK), Achieve Life Sciences (ACHV), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "medical" sector.
VolitionRx (NYSE:VNRX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.
VolitionRx presently has a consensus price target of $2.50, indicating a potential upside of 267.65%. Alpha Teknova has a consensus price target of $15.00, indicating a potential upside of 745.07%. Given VolitionRx's higher possible upside, analysts plainly believe Alpha Teknova is more favorable than VolitionRx.
VolitionRx has higher earnings, but lower revenue than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
Alpha Teknova has a net margin of -97.85% compared to Alpha Teknova's net margin of -4,379.67%. Alpha Teknova's return on equity of 0.00% beat VolitionRx's return on equity.
Alpha Teknova received 3 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 33.33% of users gave Alpha Teknova an outperform vote while only 26.67% of users gave VolitionRx an outperform vote.
VolitionRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 12.8% of VolitionRx shares are owned by company insiders. Comparatively, 15.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Alpha Teknova had 2 more articles in the media than VolitionRx. MarketBeat recorded 4 mentions for Alpha Teknova and 2 mentions for VolitionRx. VolitionRx's average media sentiment score of 1.51 beat Alpha Teknova's score of 0.67 indicating that Alpha Teknova is being referred to more favorably in the news media.
Summary
Alpha Teknova beats VolitionRx on 10 of the 17 factors compared between the two stocks.
Get Alpha Teknova News Delivered to You Automatically
Sign up to receive the latest news and ratings for TKNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Teknova Competitors List
Related Companies and Tools
